Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.
Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, Allen JR, Spurka L, Funari V, Spiteri E, Wang Q, Orsulic S, Walsh C, Karlan BY, Wiedemeyer WR.
Taylor-Harding B, et al. Among authors: cheon dj.
Oncotarget. 2015 Jan 20;6(2):696-714. doi: 10.18632/oncotarget.2673.
Oncotarget. 2015.
PMID: 25557169
Free PMC article.